高效与低效治疗对继发进展型多发性硬化的影响
结果显示,在活动性SPMS中高效治疗较低效治疗减少复发(HR 0.7,p=0.006),但在非活动性SPMS中无差异(HR 0.8,p=0.39);两组残疾进展风险均无差异。
要点
- 活动性SPMS患者高效治疗复发风险较低效治疗降低(HR 0.7)。
- 非活动性SPMS患者高效与低效治疗复发风险无差异(HR 0.8)。
- 高效治疗未显示降低SPMS患者残疾进展风险的优势。
核心结论
- 在SPMS患者中,高效治疗较低效治疗减少活动性SPMS的复发,但对非活动性SPMS无此优势,且不降低残疾进展风险。
研究设计与样本
- 基于MSBase和OFSEP两个大型观察队列的观察性研究,纳入SPMS发病后接受高效或低效治疗的患者,估计治疗滞后并用倾向评分匹配,进行配对 pairwise-censored 分析。
主要发现
- 活动性SPMS患者高效治疗组复发频率低于低效治疗组(HR 0.7,p=0.006)。
- 非活动性SPMS患者两组复发频率无差异证据(HR 0.8,p=0.39)。
- 两组残疾进展风险无差异证据。
关键数值与推荐
- 高效治疗包括natalizumab、alemtuzumab、mitoxantrone、ocrelizumab、rituximab、cladribine、fingolimod;低效治疗包括interferon beta、glatiramer acetate、teriflunomide。
- 活动性SPMS高效 vs 低效治疗复发HR 0.7(p=0.006);非活动性SPMS HR 0.8(p=0.39)。
临床怎么用
- 对于活动性SPMS患者,可考虑使用高效治疗以降低复发风险。
- 对于非活动性SPMS患者,高效治疗在减少复发方面未显示优势,且高效治疗未显示延缓残疾进展。
局限性
- 本研究为观察性研究,证据等级为Class III。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactive secondary progressive multiple sclerosis (SPMS) after accounting for therapeutic lag. METHODS: Patients treated with high-efficacy (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon beta, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and Observatoire Français de la Sclérose en Plaques (OFSEP), 2 large observational cohorts. Therapeutic lag was estimated for each patient from their demographic and clinical characteristics. Propensity score was used to match patients treated with high- and low-efficacy therapies. Outcomes after the period of therapeutic lag was disregarded were compared in paired, pairwise-censored analyses. RESULTS: One thousand patients were included in the primary analysis. Patients with active SPMS treated with high-efficacy therapy experienced less frequent relapses than those on low-efficacy therapy (hazard ratio [HR] 0.7, p = 0.006). In patients with inactive SPMS, there was no evidence for a difference in relapse frequency between groups (HR 0.8, p = 0.39). No evidence for a difference in the risk of disability progression was observed. CONCLUSION: In treated patients with SPMS, high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active but not those with inactive SPMS. However, more potent therapies do not offer an advantage in reducing disability progression in this patient group. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active SPMS, although we did not find a difference in disability progression between patients treated with high- and low-efficacy therapy.
引用
- Roos I, Leray E, Casey R, et al. Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology. 2021. PMID: 34193589. doi:10.1212/WNL.0000000000012354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。